Stericycle, Inc.

NasdaqGS:SRCL 주식 리포트

시가총액: US$5.8b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Stericycle 과거 순이익 실적

과거 기준 점검 2/6

Stericycle은 연평균 71.3%의 비율로 수입이 증가해 온 반면, Commercial Services 산업은 수입이 9.7% 증가했습니다. 매출은 연평균 3.9%의 비율로 감소했습니다. Stericycle의 자기자본이익률은 0.8%이고 순이익률은 0.8%입니다.

핵심 정보

71.30%

순이익 성장률

71.44%

주당순이익(EPS) 성장률

Commercial Services 산업 성장률8.53%
매출 성장률-3.86%
자기자본이익률0.79%
순이익률0.77%
최근 순이익 업데이트30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Seeking Alpha • Jun 04

Waste Management's Big Move Is A Win For Stericycle

Summary Waste Management announces the acquisition of Stericycle in a $7.15 billion all-cash deal, causing Stericycle shares to spike and Waste Management shares to drop. Stericycle shareholders benefit from the premium offer and can exit their position, while Waste Management's success depends on the realization of synergies and the impact on leverage. Waste Management aims to expand its environmental service offerings and gain access to Stericycle's regulated waste and compliance services, as well as its secure information destruction services. Read the full article on Seeking Alpha
Seeking Alpha • May 22

Stericycle: Watch Potential Revenue Recovery And Margin Improvement

Summary SRCL's Q1 2024 operating margins beat expectations, and the company's EBITDA margin is expected to improve significantly for full-year 2024. I anticipate that Stericycle's Secure Information Destruction segment can realize a turnaround due to a more favorable base for YoY comparison in 2H and the introduction of a subscription service. My Buy rating for SRCL stays intact following an assessment of its outlook and valuations. Read the full article on Seeking Alpha
Seeking Alpha • Mar 03

Stericycle: Earnings Beat And Above-Expectations Guidance Reinforce My Buy Rating

Summary Stericycle's normalized EPS grew by +26% QoQ in Q4 2023, and this translated into a +14% bottom line beat. The company is anticipating that its earnings will expand strongly by +24% in this new fiscal year, which is better than what Wall Street had anticipated earlier. I stick to a Buy investment rating for Stericycle stock, as I have greater confidence in SRCL's long-term prospects after reviewing its Q4 results and 2024 guidance. Read the full article on Seeking Alpha
Seeking Alpha • Aug 30

Stericycle: Muted Outlook, Fair Valuations

Summary Stericycle's revenue outlook is murky, the recovery for the secure information destruction business is still in progress, but the regulated waste and compliance segment might be affected by staffing shortages. SRCL should still record lower earnings for FY 2022 vis-a-vis FY 2021 despite delivering an EPS beat in Q2, due to higher operating and interest expenses. I continue to assign a Hold rating to Stericycle, as its valuations are reasonably fair and aligned with its full-year outlook. Elevator Pitch I rate Stericycle, Inc.'s (SRCL) stock as a Hold. I evaluated SRCL's pace of recovery from the pandemic and its capital allocation plans in an earlier October 22, 2021 article for the stock. I focus on the near-term expectations for Stericycle in this update. My analysis leads me to the conclusion that the consensus earnings forecasts implying a mid-single digit percentage decline for SRCL in FY 2022 are realistic, and Stericycle's current valuations seem to be fair taking into account the full-year outlook. As such, I maintain a Hold rating for SRCL. Revisions To Consensus Estimates The recent changes to the sell-side's consensus bottom line forecasts for Stericycle provide an indication of what the market expects of SRCL's future performance. The consensus Q3 2022 normalized earnings per share or EPS for SRCL has been revised upwards by a substantial +11% in the past one month. It is reasonable to assume that the Wall Street analysts had raised their third-quarter bottom line projections for the company in response to Stericycle's +9% EPS beat for Q2 2022. It is worthy of note that SRCL has had earnings misses for the prior four quarters between Q2 2021 and Q1 2022. But the full-year fiscal 2022 consensus numbers tell a different story. In the last one month, the market's consensus FY 2022 normalized EPS estimate ($2.06) for Stericycle has in fact been reduced slightly by -0.5%, notwithstanding SRCL's second-quarter earnings beat. Moreover, four of the eight analysts covering SRCL's shares actually lowered their EPS estimates for the company in the past month. The analysts' less than favorable view of Stericycle's full-year FY 2022 outlook might be linked to the company's most recently updated management guidance. At its Q2 2022 earnings call in early-August 2022, SRCL increased the mid-point of its FY 2022 revenue growth guidance from +4% to +5%, but it lowered the mid-point of its full-year EPS guidance from $2.15 to $2.075 (implying a -5% decline as compared to 2021 EPS of $2.19). In the rest of the article, I will assess the growth prospects of its two key business segment and the company's overall profitability. This will help to explain why company management and analysts are of the opinion that Stericycle's bottom line for FY 2022 will still contract despite above-expectations Q2 2022 earnings. Secure Information Destruction Business Performed Well in Q2 Organic revenue for Stericycle's secure information destruction business, adjusted to exclude inorganic transactions and foreign exchange effects, expanded by an impressive +12.2% YoY for the second quarter of 2022. The expectations for SRCL's secure information destruction segment weren't high, as this business faces structural challenges relating to reduced paper usage in an increasingly digitalized world. However, the company's business secure information destruction business has witnessed a meaningful recovery in Q2 2022, as pandemic restrictions are eased and an increasing number of workers return to offices. More critically, the current recovery for the secure information destruction segment still has legs to run. Stericycle highlighted at its second-quarter results briefing that "I don't think the industry has settled yet in terms of everybody being back to what is the new normal." In other words, SRCL is implying that there could be a further acceleration in the pace of people going back to offices in time to come, and this will be positive for the secure information destruction business' near-term outlook. Disappointing Performance For Regulated Waste And Compliance Services Segment In contrast with the double-digit top line growth for the secure information destruction segment in the recent quarter, Stericycle's other segment, the regulated waste and compliance services business disappointed investors with its Q2 2022 results. Specifically, the regulated waste and compliance services segment saw a very modest +1.8% YoY increase in its second-quarter organic revenue. Notably, SRCL mentioned at its Q2 2022 earnings briefing that "most of the growth" for the company's regulated waste and compliance services segment for the most recent quarter "was due to pricing." This suggests that volumes for this business was probably flattish on a YoY basis in the second quarter of this year. There are two key factors that explain why the regulated waste and compliance services business' volumes haven't grown in a meaningful way in the recent quarter. Firstly, there was a decline in COVID-19 testing and vaccinations in Q2, as COVID-19 transitions gradually into an endemic state. Secondly, the labor crunch has also affected the healthcare industry, which means that it is tough for the number of elective surgeries to return to similar levels seen before the pandemic anytime soon. Future Profitability Hurt By Operating Cost Pressures And Higher Interest Rates As discussed in an earlier section of the article, Stericycle cut its full-year FY 2022 bottom line guidance after it reported its Q2 2022 earnings. SRCL attributed this change to "higher cash operating and interest expenses" at its most recent quarterly investor call.
Seeking Alpha • Aug 04

Stericycle Q2 2022 Earnings Preview

Stericycle (NASDAQ:SRCL) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open. The consensus EPS Estimate is $0.44 (-34.3% Y/Y) and the consensus Revenue Estimate is $678.27M (+0.8% Y/Y). Over the last 2 years, SRCL has beaten EPS estimates 38% of the time and has beaten revenue estimates 50% of the time. Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward. Revenue estimates have seen 2 upward revisions and 1 downward.
Seeking Alpha • Jun 03

Stericycle: The Risks Outweigh The Reward

Stericycle seems to be in a continued state of decline, even though the pandemic is largely over. If shares were cheap enough, the company might be worth the risk, but that isn't the case either. Add in regulatory risks moving forward, and it's not worth the risk playing this name right now.
Seeking Alpha • Oct 22

Stericycle: A Neutral View

I am negative on SRCL's recovery prospects in the short term, as there has been a delay in the return of workers back to office. But I have a favorable opinion of Stericycle's capital allocation initiatives in relation to debt reduction and business or asset sales. Stericycle currently trades at consensus forward FY 2021 and FY 2022 normalized P/E multiples of 26.9 times and 25.2 times, respectively, and this seems expensive.
Seeking Alpha • Aug 08

Stericycle: A Successful Turnaround Is Likely

Revenues declined in 2018, 2019, and 2020 as the company is divesting some businesses. Long-term debt has dramatically declined in recent quarters. The company is highly profitable. Shares are down by ~55% from all-time highs in 2015. This is a turnaround play worth the risk at this price.

매출 및 비용 세부 내역

Stericycle가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqGS:SRCL 매출, 비용 및 순이익 (USD Millions)
날짜매출순이익일반관리비연구개발비
30 Sep 242,627206920
30 Jun 242,632366950
31 Mar 242,640-196960
31 Dec 232,659-217070
30 Sep 232,678-46980
30 Jun 232,715227050
31 Mar 232,725816980
31 Dec 222,705567070
30 Sep 222,69277070
30 Jun 222,650-877000
31 Mar 222,643-686860
31 Dec 212,647-287160
30 Sep 212,646386340
30 Jun 212,633236310
31 Mar 212,559-116200
31 Dec 202,676-577300
30 Sep 202,820-3256770
30 Jun 203,016-3036980
31 Mar 203,264-3297530
31 Dec 193,309-3478540
30 Sep 193,362-4468100
30 Jun 193,384-3697840
31 Mar 193,421-3128160
31 Dec 183,486-2531,0430
30 Sep 183,5211488260
30 Jun 183,5491668120
31 Mar 183,583-98140
31 Dec 173,581238400
30 Sep 173,599-479870
30 Jun 173,607-211,0250
31 Mar 173,5811659650
31 Dec 163,5621787770
30 Sep 163,5442367150
30 Jun 163,3732446610
31 Mar 163,1972956050
31 Dec 152,9862575940
30 Sep 152,7752695060
30 Jun 152,7242824950
31 Mar 152,6492764820
31 Dec 142,5563264340
30 Sep 142,4473224280
30 Jun 142,3133204080
31 Mar 142,1993163840
31 Dec 132,1433113800

양질의 수익: SRCL는 $78.4M 규모의 큰 일회성 손실이 있어 30th September, 2024까지 지난 12개월 재무 결과에 영향을 미쳤습니다.

이익 마진 증가: SRCL는 과거에 흑자전환했습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: SRCL는 지난 5년 동안 흑자전환하며 연평균 71.3%의 수익 성장을 기록했습니다.

성장 가속화: SRCL는 지난해 흑자전환하여 5년 평균과 수익 성장률을 비교하기 어렵습니다.

수익 대 산업: SRCL는 지난해 흑자전환하여 지난 해 수익 성장률을 Commercial Services 업계(7.2%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: SRCL의 자본 수익률(0.8%)은 낮음으로 평가됩니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2024/11/04 05:57
종가2024/11/01 00:00
수익2024/09/30
연간 수익2023/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Stericycle, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Gary BisbeeBarclays
Alexander ParisBarrington Research Associates, Inc.
Kevin SteinkeBarrington Research Associates, Inc.